Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs
IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition
WALTHAM, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced that the first patient has been dosed in the INDIGO Phase 3 registrational study of obexelimab. The INDIGO study will evaluate the clinical efficacy and safety of obexelimab treatment in the prevention of IgG4-related disease (IgG4-RD) flare. Obexelimab is a high-affinity bifunctional antibody that inhibits B-cell lineages by simultaneously binding to CD19 and FcƳRIIB, thereby downregulating B-cell activity in patients with autoimmune diseases associated with autoantibodies, such as IgG4-RD.
“IgG4-RD is a chronic and serious fibroinflammatory condition that can affect nearly any organ system and can have a profound impact on many patients, leading to severe organ damage or death,” said Hua Mu, M.D., Ph.D., Chief Executive Officer at Zenas. “There are no currently approved treatments for patients living with IgG4-RD. Based upon the promising data from a Phase 2 study of obexelimab in IgG4-RD patients, we are excited to continue to evaluate the potential of obexelimab in the INDIGO study.”
About the INDIGO Study
The INDIGO study is a global multicenter, randomized, double-blind, placebo-controlled study enrolling up to 200 adults with active IgG4-RD signs/symptoms (i.e., flare) that require steroid therapy. Patients will be randomized in a ratio of 1:1 to receive either obexelimab or placebo, administered as subcutaneous injections.
The primary endpoint of INDIGO is time to first IgG4-RD flare (defined as the reappearance of previous signs/symptoms or appearance of new signs/symptoms of IgG4-RD) that requires initiation of rescue therapy from randomization to Week 52. Safety will be evaluated throughout the study duration.
More information on the INDIGO study (NCT05662241) is available at clinicaltrials.gov.
About Obexelimab
Obexelimab is an investigational Phase 3-stage, novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. Simultaneous binding to CD19 and FcƳRIIB by obexelimab mimics a natural antigen-antibody complex and downregulates B cell activity. In several early-stage clinical studies, 198 subjects were treated with obexelimab. In these clinical studies, the molecule demonstrated effective inhibition of B cell function without depleting the cells and generated an encouraging treatment effect in patients with multiple autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc.
About IgG4-RD
IgG4-RD is a chronic and serious fibroinflammatory disease typically affecting multiple organs (e.g., pancreas, liver, kidney, bile duct, salivary and lacrimal glands). Approximately 20,000 people are diagnosed with IgG4-RD in the US, with similar prevalence rates across geographies. Many patients have some degree of irreversible organ damage at the time of diagnosis. Although nearly all patients initially respond to glucocorticoid (GC) therapy, a majority of patients will relapse/flare within a few months of discontinuing treatment, requiring rescue therapy. Chronic GC therapy is also associated with toxicity in many patients.
About Zenas BioPharma
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment. The company’s pipeline continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those living with autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.
Investor and Media Contact:
Joe Farmer, President & COO
Zenas BioPharma
IR@zenasbio.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Prospera Energy PEI ESG Initiatives Reduces Asset Retirement Liability Commendably and Gains the Principal Investors Support and Guidance to Increase ESG Efforts Effectually29.3.2023 08:01:43 CEST | Press release
CALGARY, Alberta, March 29, 2023 (GLOBE NEWSWIRE) -- Prospera Energy Inc.PEI: TSX-V; OF6A: FRA, OTC: GXRFF Approximately, two years ago Prospera was restructured to be profitable and compliant from a terminal position. Although the focus was to increase production rapidly, Prospera has commendably managed to address 400+ non-compliances and abandoned 60 wells. As a result, PEI has elevated the regulator License Liability Rating (LLR) from a deficit 0.37 past the regulator requirement (LLR=1) to surplus 1.2, erasing the liability deficit of 9+ Cdn million$ driving PEI to an asset surplus of approximately 4 Cdn million$. This is only the first-year result of a three-year liability management plan (LMR). Prospera’s commitment is to effectually implement the environmentally friendly ESG initiatives (eliminate emissions and reduce environmental footprint). Therefore, PEI has strategically engaged Philanthropist and PEI principal investor Mr. Dave Richardson and Engineering Specialist Angela
Fluence Launches Ultrastack, its Highest-Performance Energy Storage Product to Date, to Transform Transmission and Distribution Grids29.3.2023 08:00:00 CEST | Press release
Fluence Ultrastack™ deployed as a transmission asset will reduce energy costs to customers by decreasing expenses of operating and developing network infrastructure through managing renewable curtailment, increasing utilization of existing power lines, and limiting congestions.Network owners and operators will have access to next-generation, patent-pending advanced controls and critical applications with very high (more than 99%) reliability to ensure grid stability during contingency events and increased energy security. ARLINGTON, Va., March 29, 2023 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (“Fluence”) (NASDAQ: FLNC), a leading global provider of energy storage products, services, and cloud-based software for renewables and storage, announced today the release of Fluence Ultrastack™. Ultrastack is an advanced energy storage product designed to transform the way transmission and distribution networks operate around the world by addressing some of the main challenges created by the ene
Meeting Professionals International (MPI) announces Luxembourg as location for its 2024 signature event, the European Meetings and Events Conference (EMEC)29.3.2023 08:00:00 CEST | Press release
Thanks to its foundational creation pillars, EMEC establishes a path for growth of the global events industry. Brighton, UK, March 29, 2023 (GLOBE NEWSWIRE) -- Meeting Professionals International (MPI), the largest meeting and event industry organisation worldwide, is excited to announce that it has chosen the Grand Duchy of Luxembourg as the host destination for the 2024 edition of its award-winning signature event, European Meetings and Events Conference (EMEC). Now in its 35th year, and attracting more than 300 attendees annually, EMEC is the European community’s premier event for meeting and event professionals. Purposefully designed by Europeans for Europeans, MPI strives to find destinations for its global events that are aligned with its mission. Through an extensive, competitive Request for Proposal process, Luxembourg was chosen for its ability to deliver unique learning experiences based on a combination of its diverse range of attractions, unique dining experiences and centr
Huhtamäki Oyj: Notice to the Annual General Meeting29.3.2023 08:00:00 CEST | Press release
HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 29.3.2023 AT 9:00 EEST Huhtamäki Oyj: Notice to the Annual General Meeting Notice is given to the shareholders of Huhtamäki Oyj (the “Company”) to participate in the Annual General Meeting to be held on Thursday, April 27, 2023, at 11:00 a.m. (EEST) at Marina Congress Center, Katajanokanlaituri 6, 00160 Helsinki, Finland. Reception of shareholders who have registered for the meeting and distribution of voting tickets will commence at 10:00 a.m. (EEST). Shareholders may follow the Annual General Meeting via a webcast. The webcast is available for those shareholders who have registered for the webcast and are also registered in the Company's shareholders’ register maintained by Euroclear Finland Ltd on the record date of the Annual General Meeting, April 17, 2023. Instructions on how to register as a follower for the webcast and how to follow the webcast are available on the Company’s website (www.huhtamaki.com). It is not possible to present question
Flex LNG - 2023 Annual General Meeting29.3.2023 08:00:00 CEST | Press release
Hamilton, Bermuda March 29, 2023 FLEX LNG LTD. (the “Company”) advises that the 2023 Annual General Meeting of the Company will be held on May 8, 2023. The record date for voting at the Annual General Meeting is set to April 11, 2023. The notice, agenda and associated material will be distributed prior to the meeting. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act